<DOC>
	<DOCNO>NCT01917890</DOCNO>
	<brief_summary>Prostate cancer second incident cancer among male population worldwide . Radiation therapy along surgery chemotherapy main treatment prostate cancer however prostate cancer cell modestly responsive even unresponsive cytotoxic effect radiotherapy . Recently vitro vivo study show radiosensitizing radioprotective effect curcumin . No clinical trial do area yet know whether radiation therapy effective without curcumin supplement treat patient prostate cancer .</brief_summary>
	<brief_title>Radiosensitizing Radioprotectve Effects Curcumin Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Curcumin</mesh_term>
	<criteria>1 . Histologically confirm adenocarcinoma prostate 2 . Age range 5080 3 . ECOG performance status 01 4 . Life expectancy &gt; 5 year 5 . Must enrol social security program 6 . No cancer , except basal cell skin cancer , treat relapse within past 5 year 7 . No severe uncontrolled hypertension ( systolic BP ≥ 160 mm Hg diastolic BP ≥ 90 mm Hg ) 8 . No contraindication luteinizing hormonereleasing hormone agonists 9 . No contraindication pelvic irradiation ( e.g. , scleroderma , chronic inflammatory gastrointestinal disease ) 10 . No hip prosthesis 11 . Must deprive liberty guardianship 12 . No geographical , social , psychological reason would preclude follow 1 . Clinical stage T3 T4 2 . Gleason score ≥ 8 3 . Serum PSA ≥ 20 ng/mL ≤ 100 ng/mL 4. prior surgery prostate cancer 5. concurrent participation another clinical trial would require approval upon entry trial 6 . Gastrointestinal disorder IBD , reflux peptic ulcer 7 . Any adverse reaction curcumin</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>curcumin</keyword>
	<keyword>radioprotective</keyword>
	<keyword>radiosensitizer</keyword>
</DOC>